Clinical

Dataset Information

0

Lapatinib Plus Trametinib in KRAS Mutant NSCLC


ABSTRACT: This is an open-label phase I/II multi-center study consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of lapatinib combined with trametinib in patients with metastatic KRASm and PIK3CA wild-type (PIK3CAwt) non-small cell lung cancer (NSCLC). Part B is designed to perform a randomized comparison of the lapatinib-trametinib combination versus standard of care therapy in patients with metastatic KRASm/PIK3CAwt NSCLC.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2173655 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2017-05-02 | GSE98399 | GEO
| 2159017 | ecrin-mdr-crc
2015-10-06 | GSE66305 | GEO
2015-10-06 | GSE66398 | GEO
2024-05-17 | GSE236258 | GEO
2012-06-30 | GSE38376 | GEO
2013-10-31 | GSE51889 | GEO
2021-07-19 | E-MTAB-9889 | biostudies-arrayexpress
2013-10-31 | E-GEOD-51889 | biostudies-arrayexpress
2024-08-23 | PXD051094 | Pride